Adherent cells from adipose or placenta tissues and use thereof in therapy
A method of treating ischemia in a subject in need thereof is disclosed. The method comprising administering to the subject a therapeutically effective amount of adherent cells of a tissue selected from the group consisting of a placenta and an adipose tissue, thereby treating the ischemia in the subject. A method of treating a medical condition requiring connective tissue regeneration and/or repair is also disclosed.
1. A method of treating a wound in a subject in need thereof, comprising systemically administering to the subject a therapeutically effective amount of undifferentiated placenta-derived adherent stromal cells in a liquid suspension, wherein the adherent stromal cells do not express CD34, thereby treating the wound.
2. The method of claim 1 , wherein at least 10% of said cells are at a proliferative phase.
3. The method of claim 1 , wherein the wound is a wound to the skin.
4. The method of claim 1 , wherein said cells have been propagated in three-dimensional (3D) culturing conditions.
5. The method of claim 4 , wherein said three-dimensional (3D) culturing conditions comprise a 3D bioreactor.
6. The method of claim 4 , wherein said three-dimensional (3D) culturing conditions are effected under perfusion.
7. The method of claim 4 , wherein said three-dimensional (3D) culturing conditions comprise an adherent material selected from the group consisting of a polystyrene, a polyester, and a polypropylene.
8. The method of claim 1 , wherein said cells have been cultured for at least 3 days.
9. The method of claim 1 , wherein said cells have been cultured until at least 10% of said cells are proliferating.
10. The method of claim 4 , wherein said cells express a marker selected from the group consisting of CD73, CD90, CD29 and CD105.
11. The method of claim 4 , wherein said cells do not express a marker selected from the group consisting of CD3, CD4, CD45, CD80, HLA-DR, CD11b, CD14, CD19 and CD79.
12. The method of claim 6 , wherein said perfusion rate is adjusted in order to maintain a constant glucose concentration in the culture medium.
13. The method of claim 12 , wherein said constant glucose concentration is about 550 mg/L.
14. The method of claim 1 , wherein said cells have been propagated in two-dimensional (2D) culturing conditions.
15. The method of claim 14 , wherein said cells express a marker selected from the group consisting of CD90, CD105, CD73 and CD29.
16. The method of claim 1 , wherein treating the wound comprises treating delayed wound healing.
17. The method of claim 16 , wherein the wound is an ulcer.
18. The method of claim 17 , wherein the ulcer wound is to the skin.
19. The method of claim 3 , wherein the wound to the skin is an ulcer.
20. The method of claim 1 , wherein the undifferentiated placenta-derived adherent stromal cells are non-autologous to the subject.
21. A method of preparing cells for treating a wound in a subject in need thereof, the method comprising expanding placenta-derived adherent stromal cells in culture, wherein when the culture-expanded placenta-derived adherent stromal cells are subsequently systemically administered in a liquid suspension to a subject in a therapeutically effective amount they treat a wound in the subject.
22. The method of claim 21 , wherein the culture is a 3D culture.
23. The method of claim 22 , wherein said placenta-derived adherent stromal cells are non-autologous to the subject.
24. A method of preparing cells for treating a wound in a subject in need thereof, the method comprising expanding non-autologous placenta-derived adherent stromal cells in three-dimensional culture, wherein when the culture-expanded placenta-derived adherent stromal cells are subsequently systemically administered in a liquid suspension to the subject in a therapeutically effective amount they treat a wound in the subject.